TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05453162

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy for Posttraumatic Stress Disorder
Description: Manualized procedures deliver ten 90-minute sessions targeted to occur weekly and administered via tele-health with the same study therapist. Session 1 will focus on psychoeducation. Session 2 involves construction of the in vivo exposure hierarchy. Sessions 3-10 focus on in-session imaginal exposures to the worst trauma memory for 45-60 min followed by 15-20 min of processing the imaginal exposure. For homework, participants will be instructed to confront situations on their hierarchy on a daily basis using recording of their imaginal exposure. Subjective Units of Distress (SUDS) ratings will be taken throughout imaginal exposure exercises.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy for Posttraumatic Stress Disorder
Description: Manualized procedures deliver ten 90-minute sessions targeted to occur weekly and administered via tele-health with the same study therapist. Session 1 will focus on psychoeducation. Session 2 involves construction of the in vivo exposure hierarchy. Sessions 3-10 focus on in-session imaginal exposures to the worst trauma memory for 45-60 min followed by 15-20 min of processing the imaginal exposure. For homework, participants will be instructed to confront situations on their hierarchy on a daily basis using recording of their imaginal exposure. Subjective Units of Distress (SUDS) ratings will be taken throughout imaginal exposure exercises.
Study: NCT05927545

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient education and preventive exercise
Description: Educational training program and prevention exercises about temporomandibular dysfunction in patients with temporomandibular dysfunction-associated headaches.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient education, preventive exercise combined with Manual Therapy protocol
Description: Manual therapy program combined with the educational training program and prevention exercise about temporomandibular dysfunction in patients with temporomandibular dysfunction-associated headaches.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient education, preventive exercise combined with BETY approach
Description: BETY therapy program combined with the educational training program and prevention exercise about temporomandibular dysfunction in patients with temporomandibular dysfunction-associated headaches.
Study: NCT04175574

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: The music has no lyrics, has a sustained melodic quality, has no strong rhythms and percussion or base, rate of 60-80 beats per minute, promotes relaxation, calming and soothing, neutral and is unbiased towards any culture or age. The volume of the music will be pre-adjusted to the patients' preference (preferable 30 dB) by the research assistant.
Study: NCT05506488

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib 100 MG + Quercetin (1000 MG)
Description: The intervention group will receive intermittent orally administered dasatinib (100 mg/day) plus quercetin (1000 mg/day) on three consecutive days for three consecutive weeks followed by a four-week medication free period. This cycle will be repeated three times.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group will receive intermittent orally administered placebo tablets on three consecutive days for three consecutive weeks followed by a four-week medication free period. This cycle will be repeated three times.
Study: NCT05472506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IK-175 + nivolumab
Description: IK-175 + nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IK-175 + nivolumab
Description: IK-175 + nivolumab
Study: NCT04995042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR7280
Description: Drug: SHR7280 All participants receive SHR7280 alone.
Study: NCT06369584

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prone position
Description: The process of prone positioning requires 5-6 people, with one person acting as the commander responsible for directing and monitoring. The process of monitoring includes ECMO flow and the vital signs. The second person is in charge of the patient's head, including endotracheal intubation, ventilator lines, and jugular ECMO cannula. The third person is responsible for femoral ECMO cannula and central venous line. The fourth to sixth individuals are responsible for rotating the patient's torso towards the side without an ECMO tube. Before initiating prone ventilation, pressure ulcer protection patches should be placed on the patient's forehead, ears, anterior chest, and iliac crest to protect areas under pressure. During ECMO support period, each patient needs to undergo at least four sessions of prone ventilation until their condition improves enough to discontinue ECMO support. Each session should last between 16 to 24 hours.
Study: NCT05734690

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGLT2i, beta blocker, ARNI, MRA, MTD
Description: Immediate initiation of guideline-directed medical therapy. Will also immediately receive the same educational services provided in the Education-First intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2i, beta blocker, ARNI, MRA, MTD
Description: Immediate initiation of guideline-directed medical therapy. Will also immediately receive the same educational services provided in the Education-First intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education-First
Description: For the first 3-months of their participation, patients in this arm will receive curated patient education, an alert to providers, provider education, and then after 3 months, be invited to participate in the remote heart failure clinic. The patient education would consist of curated video content and informational worksheets provided by email or secure patient messaging. Provider alerts would happen through notifying of a patient's eligibility for heart failure therapy. Provider education will also consist of the program's medical algorithm and a summary sheet on indications, outcomes, prescribing, and monitoring information
Study: NCT05823623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inetetamab
Description: Patients with HER2-positive metastatic breast cancer after progression on trastuzumab are enrolled and receive treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Patients with HER2-positive metastatic breast cancer after progression on trastuzumab are enrolled and receive treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Vinorelbine Tartrate
Description: Patients with HER2-positive metastatic breast cancer after progression on trastuzumab are enrolled and receive treatment.
Study: NCT05821842

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sonu
Description: Acoustic energy delivery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sonu
Description: Acoustic energy delivery
Study: NCT04250623

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health care product (gel)
Description: hyaluronic acid intimate moisturizing gel (to be applied on the subject's skin)
Study: NCT05873205

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: All participants enrolled on the study will receive isatuximab intravenously as a single agent
Study: NCT05850962

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individualised MAP target
Description: The project will test an intervention that initially targets a patient's own pre-illness mean arterial pressure (MAP) during vasopressor support in ICU. The pre-illness MAP will be estimated from the most recent pre-illness BP readings recorded in medical records.
Study: NCT04637100

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile or tablet-based gaming applications
Description: Subject will use their own personal smartphone or tablet device to play from a collection of pre-selected gaming applications. The collection is made of puzzle-type games available on both Android and iOS without excessive ads and with clear or self-explanatory instructions. Subject will be instructed to play for 1 hour daily for the duration of their acute inpatient rehabilitation stay (approximately 3 weeks).
Study: NCT06035744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLN-617
Description: Single-chain fusion protein comprised of human IL-2, human LAIR2, HSA, and human IL-12, connected via glycine/serine linker sequences

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLN-617
Description: Single-chain fusion protein comprised of human IL-2, human LAIR2, HSA, and human IL-12, connected via glycine/serine linker sequences

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLN-617
Description: Single-chain fusion protein comprised of human IL-2, human LAIR2, HSA, and human IL-12, connected via glycine/serine linker sequences

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Humanized IgG4 anti-PD-1 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Humanized IgG4 anti-PD-1 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Humanized IgG4 anti-PD-1 monoclonal antibody
Study: NCT05173415

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirius Pintution
Description: The intervention studies a metal Clip (Sirius Pintution) to localize axillary lymph nodes during TAD. Intraoperative localization of the lymph node will be conducted using a hand-held probe identifying the clip.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HydroMARK (C) Clip
Description: The control intervention is a metal clip (HydroMARK© Clip), which will be localized and extracted during the tailoring surgery. Intraoperative Ultrasound is used to localize the clip. This method is considered as standard practice today.
Study: NCT04637100

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stroke-related educational videos
Description: Subject will use their own personal smartphone or tablet device to watch videos from a collection of pre-selected educational videos. These include topics on stroke recognition, stroke recovery process, patient experiences with stroke, rehabilitation after stroke, activities of daily living equipment instructions. Subject will be instructed to watch for 1 hour daily for the duration of their acute inpatient rehabilitation stay (approximately 3 weeks).
Study: NCT04678349

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PHGG
Description: Subjects will be given 4 scoops (40g) PHGG, which provide 160kcal, 0.24g protein, 30.4g soluble fibre, 40g carbohydrate and 0g sugar, once allowed orally.

Intervention type: OTHER
Group type: OTHER
Intervention: conventional care
Description: follow low fibre diet and anti-diarrhea drugs
Study: NCT05528068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: supervised lifestyle intervention
Description: Participants will receive personalized dietary and exercise prescription according to the assessment of nutritional status, physical fitness and physiological-biochemical indexes. The participants will use the digital application for the first 3 months with supervised lifestyle intervention. Wearable devices, such as ambulatory blood pressure monitoring, dynamic electrocardio scanner and smart watch, will be worn to provide continuous physiological monitoring for safety. And then, participants will use the application by self-management for the next 6 months. All participants are given questionnaires, nutritional, physical fitness and physiological-biochemical assessment at baseline, 3 months, 6 months and 9 months.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: healthy lifestyle education
Description: Participants will receive standard care and healthy lifestyle education for hypertension prevention and control. Wearable devices, such as ambulatory blood pressure monitoring, dynamic electrocardio scanner and smart watch, will be worn to provide continuous physiological monitoring for safety. Participants will use the application by self-management for 9 months. All participants are given questionnaires, nutritional, physical fitness and physiological-biochemical assessment at baseline, 3 months, 6 months and 9 months.
Study: NCT05755347

Intervention type: OTHER
Intervention: General health survey questionnaires
Description: Patient-reported outcome survey will be offered at baseline.

Intervention type: OTHER
Intervention: PROMIS Cancer Function Brief 3D profile questionnaires
Description: Patient-reported outcome survey will be offered at baseline.

Intervention type: OTHER
Intervention: FACT-G questionnaires
Description: Patient-reported outcome survey will be offered at baseline.

Intervention type: OTHER
Intervention: Godin Leisure-Time Exercise Questionnaire
Description: Patient-reported outcome survey will be offered at baseline.

Intervention type: OTHER
Intervention: REAP-S questionnaires
Description: Patient-reported outcome survey will be offered at baseline.
Study: NCT06359028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stannous fluoride toothpaste
Description: Toothpaste containing 0.454 % weight/weight (w/w) SnF2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crest cavity protection toothpaste
Description: Regular fluoride toothpaste containing 1100 parts per million (ppm) fluoride.
Study: NCT05014503

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adaptive Therapeutic gaming
Description: All children will be asked to use the adaptive version of the therapeutic game for three months, during their free time, at home or at the special school where they stay. They will be asked to play the game minimally three times per week between 20-30 minutes per session. The researchers will install the game on a device of choice for the children. Back-up devices are available from the study team to ensure that children having no suitable device can participate in the study. The parent and/or caretaker will be asked to support the child in starting the program, but not to intervene during the actual game time. The game is designed to ensure that children can play independently. Therefore, children will be able to play at home, at school or during their free time. The program will not replace their regular therapy program, but will be provided additionally. The number of regular therapy hours will however be registered.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-adaptive Therapeutic gaming
Description: All children will be asked to use the non-adaptive version of the therapeutic game for three months, during their free time, at home or at the special school where they stay. They will be asked to play the game minimally three times per week between 20-30 minutes per session. The researchers will install the game on a device of choice for the children. Back-up devices are available from the study team to ensure that children having no suitable device can participate in the study. The parent and/or caretaker will be asked to support the child in starting the program, but not to intervene during the actual game time. The game is designed to ensure that children can play independently. Therefore, children will be able to play at home, at school or during their free time. The program will not replace their regular therapy program, but will be provided additionally. The number of regular therapy hours will however be registered.
Study: NCT05309213

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IM19 CAR-T cells
Description: IM19 CAR-T cells will be administered at dose level:5 x 10\^4 CAR+ T cells/kg,1x 10\^5 CAR+ T cells/kg,3 x 10\^5 CAR+ T cells/kg,1 x 10\^6 CAR+ T cells/kg
Study: NCT04557475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Two tablets daily with dinner
Study: NCT06402149

Intervention type: OTHER
Intervention: dexamethasone
Description: Use of dexamethasone in infraclavicular block
Study: NCT05647928

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT05884294

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PowerGlide Pro Midline catheter.
Description: The Intervention Group will be represented by hospitalized adult clinical patients who have been identified with difficult intravenous access. These patients will receive an ultrasound-guided insertion of the PowerGlide ProTM Midline 20G (10 cm).
Study: NCT05256719

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg
Description: Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg , i.v. single dose usage.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg
Description: Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg , i.v. single dose usage.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg
Description: Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg , i.v. single dose usage.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg
Description: Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg , i.v. single dose usage.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg
Description: Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg , i.v. single dose usage.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-1mg/kg
Description: Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-2.5mg/kg
Description: Recombinant human CTLA-4-FC fusion protein for injection 2.5mg/kg

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-5mg/kg
Description: Recombinant human CTLA-4-FC fusion protein for injection 5mg/kg

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-7.5mg/kg
Description: Recombinant human CTLA-4-FC fusion protein for injection 7.5mg/kg

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-10mg/kg
Description: Recombinant human CTLA-4-FC fusion protein for injection 10mg/kg
Study: NCT06632119

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high-intensity laser therapy
Description: high-intensity laser therapy (HILT) machine, ASA laser

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham-HILT
Description: Sham-HILT, HILT machine without laser release
Study: NCT06634264

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft Oral Appliance
Description: Ora-Motor training of oral muscles (tongue, lips) associated with nasal hygiene, with reduced parental support.
Study: NCT05326282

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Multi-parametric ultrasound
Description: Diagnostic ultrasound parameters used to evaluate the prostate. Transrectal scans will be performed
Study: NCT05055583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab in Combination With Platinum-based Chemotherapy
Description: Toripalimab will be administered at a fixed dose of 80 mg (2ml)/vial, IV, D1, with a full dose of 240 mg at one time, every 3 weeks for 3-4 cycles. Squamous cell carcinoma will be combined with cisplatin/carboplatin and Nab-paclitaxel: carboplatin, AUC=5, D1, IV, q3w, or cisplatin, 75 mg/m2, IV, q3w, and Nab-paclitaxel, 130 mg/m2, D1, IV, q3w, for 3-4 cycles. Non-squamous cell carcinoma will be combined with cisplatin/carboplatin and Pemetrexed, cisplatin/carboplatin is the same as above, Pemetrexed will be given at 500 mg/m2, D1, IV, q3w, for 3-4 cycles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical treatment stage
Description: After the last treatment (Day 21 of Cycle 4), surgery was performed within 4-6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant treatment stage
Description: Postoperatively, a comprehensive evaluation will be conducted by the investigator, and the intention will receive maintenance therapy within 6-12 weeks of the MDT assessment. Toripalimab: a fixed dose of 80 mg (2ml)/vial, IV, D1, a full dose of 240 mg at one time, every 3 weeks administered until PD or intolerable toxicity, for a maximum duration of 1 year.